The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1652
ISSUE1652
June 13, 2022
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
June 13, 2022 (Issue: 1652)
The FDA has approved tenapanor (Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment of irritable bowel syndrome
with constipation (IBS-C) in adults. Tenapanor is the
first NHE3 inhibitor to become...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.